Order Article Reprints

Cieślikowski WA, Milecki P, Świerczewska M, Ida A, Kasperczak M, Jankowiak A, Nowicki M, Pantel K, Alix-Panabières C, Zabel M, et al. Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer. Journal of Personalized Medicine. 2023; 13(4):608. https://doi.org/10.3390/jpm13040608

Cieślikowski, Wojciech A., Piotr Milecki, Monika Świerczewska, Agnieszka Ida, Michał Kasperczak, Agnieszka Jankowiak, Michał Nowicki, Klaus Pantel, Catherine Alix-Panabières, Maciej Zabel, and et al. 2023. "Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer" Journal of Personalized Medicine 13, no. 4: 608. https://doi.org/10.3390/jpm13040608

Cieślikowski, W. A., Milecki, P., Świerczewska, M., Ida, A., Kasperczak, M., Jankowiak, A., Nowicki, M., Pantel, K., Alix-Panabières, C., Zabel, M., Antczak, A., & Budna-Tukan, J. (2023). Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer. Journal of Personalized Medicine, 13(4), 608. https://doi.org/10.3390/jpm13040608